Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia

Acta Haematologica

Volumn 133, Issue 3, 2015, Pages 287-294

  Brunetta, Denise Menezes ^a   De Santis, Gil Cunha ^a   Silva Pinto, Ana Cristina ^a   Oliveira De Oliveira, Luciana Correa ^a   Covas, Dimas Tadeu ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemostasis; Hydroxyurea; Microparticles; Sickle cell anemia

Indexed keywords

D DIMER; HYDROXYUREA; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; ANTISICKLING AGENT; ANTITHROMBIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ARTICLE; BLOOD CLOTTING; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM; ERYTHROBLAST; ERYTHROCYTE COUNT; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MICROPARTICLE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT OUTCOME; ADULT; ANEMIA, SICKLE CELL; ANIMAL; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; MEMBRANE MICROPARTICLE; METABOLISM; MONOCYTE; PATHOLOGY; VASCULAR ENDOTHELIUM;

ADULT; ANEMIA, SICKLE CELL; ANIMALS; ANTISICKLING AGENTS; ANTITHROMBINS; CELL-DERIVED MICROPARTICLES; ENDOTHELIUM, VASCULAR; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; MALE; MEGALOBLASTS; MONOCYTES; THROMBOPLASTIN;

EID: 84928425939     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000362148     Document Type: Article

References (44)

1. Ataga KI, Key NS: Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007, pp 91-96.
2. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohier C, Hinderliter A, Parise LV, Orringer EP: Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008; 93: 20-26.
3. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ: Sickle cell disease: the neurological complications. Ann Neurol 2002; 51: 543-552.
4. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD: Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001; 125: 1436-1441.
5. Tomer A, Harker LA, Kasey S, Eckman JR: Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137: 398-407.
6. Francis RB Jr: Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991; 2: 341-353.
7. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P: Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 1999; 134: 352-362.
8. Allan D, Limbrick AR, Thomas P, Westerman MP: Microvesicles from sickle erythrocytes and their relation to irreversible sickling. Br J Haematol 1981; 47: 383-390.
9. Allan D, Limbrick AR, Thomas P, Westerman MP: Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature 1982; 295: 612-613.
10. Key NS, Kwaan HC: Microparticles in thrombosis and hemostasis. Semin Thromb Hemost 2010; 36: 805-806.
11. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
12. Boulanger CM: Microparticles, vascular function and hypertension. Curr Opin Nephrol Hypertens 2010; 19: 177-180.
13. Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A: Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011; 106: 310-321.
14. Goichot B, Grunebaum L, Desprez D, Vinzio S, Meyer L, Schlienger JL, Lessard M, Simon C: Circulating procoagulant microparticles in obesity. Diabetes Metab 2006; 32: 82-85.
15. Nomura S: Statin and endothelial cell-derived microparticles. Thromb Haemost 2008; 100: 377-378.
16. De Franceschi L, Cappellini MD, Olivieri O: Thrombosis and sickle cell disease. Semin Thromb Hemost 2011; 37: 226-236.
17. Ataga KI, Orringer EP: Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115: 721-728.
18. Rees DC, Williams TN, Gladwin MT: Sicklecell disease. Lancet 2010; 376: 2018-2031.
19. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, De-Castro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
20. Aslan M, Freeman BA: Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med 2007; 43: 1469-1483.
21. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP: Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 2678-2683.
22. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J: Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142: 126-135.
23. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F: Platelet activation in patients with sickle cell disease. Br J Haematol 1998; 100: 741-749.
24. van Tits LJ, van Heerde WL, Landburg PP, Boderie MJ, Muskiet FA, Jacobs N, Duits AJ, Schnog JB: Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun 2009; 390: 161-164.
25. Noubouossie DC, Le PQ, Rozen L, Debaugnies F, Ferster A, Demulder A: Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 2012; 130: 259-264.
26. Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I: The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 2012; 107: 1044-1052.
27. Nebor D, Romana M, Santiago R, Vachiery N, Picot J, Broquere C, Chaar V, Doumdo L, Odievre MH, Benkerrou M, Elion J: Fetal hemoglobin and hydroxycarbamide modulate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica 2013; 98: 862-867.
28. Lofvenberg E, Nilsson T, Wahlin A, Jacobsson L: Hydroxyurea treatment of myeloproliferative disorders. Macro-megaloblastic blood and bone marrow changes. Acta Med Scand 1987; 222: 169-174.
29. Seki JT, Al-Omar HM, Amato D, Sutton DM: Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Ann Pharmacother 2003; 37: 675-678.
30. Kramer OH, Knauer SK, Zimmermann D, Stauber RH, Heinzel T: Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008; 27: 732-740.
31. Pearson HA, Spencer RP, Cornelius EA: Functional asplenia in sickle-cell anemia. N Engl J Med 1969; 281: 923-926.
32. Koc A, Gumruk F, Gurgey A: The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol 2003; 20: 429-434.
33. van Beers EJ, Peters M, Biemond BJ: Pathophysiology and treatment of sickle-cell disease (in Dutch). Ned Tijdschr Geneeskd 2005; 149: 1144-1149.
34. Qari MH, Dier U, Mousa SA: Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost 2012; 18: 195-200.
35. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, Zielinski C, Pabinger I: Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10: 1363-1370.
36. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF: Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res 2005; 116: 409-419.
37. Aharon A, Brenner B: Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22: 61-69.
38. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH: Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105: 1515-1522.
39. Lacroix R, Dignat-George F: Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res 2012; 129(suppl 2):S27-S29.
40. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, Asfar P, Martinez MC, Andriantsitohaina R: Circulating microparticles from patients with septic shock exert a protective role in vascular function. Am J Respir Crit Care Med 2008; 178: 1148-1155.
41. Guervilly C, Lacroix R, Forel JM, Roch A, Camoin-Jau L, Papazian L, Dignat-George F: High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care 2011; 15:R31.
42. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F: Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
43. Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F: Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013, Epub ahead of print.
44. Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM: Pre-analytical issues in the measurement of circulating microparticles: Current recommendations and pending questions. J Thromb Haemost 2013; 11: 693-696.